With an accelerated interest for automation in the manufacturing space along with intensified domestic policies, 美国制药工业正在迅速发展. 根据麦肯锡和制药制造业的报告, pharmaceutical has been historically slower to implement automation and digitalisation compared to other manufacturing sectors. 然而, the new intensified ‘Buy American’ policies and the Covid-19 pandemic are expected to change – and accelerate – the adoption of robotics in the US pharmaceutical manufacturing sector.


Business conditions for US pharmaceutical manufacturers are changing rapidly by forces including intense global pricing pressures, 高度脆弱的全球供应链, 以及越来越多的国内保护主义政策. 根据食品和药物管理局(FDA)和国家卫生研究院发表的文章, 新冠肺炎大流行加速了制造业回流美国的步伐, as the country’s vulnerability to supply chain fluctuations of generic drugs and medical supplies became particularly apparent during the pandemic. The heightening concern of US dependence on 中国 for critical medical and pharmaceutical supplies pushed the Trump administration to introduce the executive order of 《2020年中国药品供应链保护法案》. This act mapped out reshoring initiatives to incentivise large American pharmaceutical companies to bring their production facilities closer to home (US. 国会的年代.3537). 再加上特朗普和拜登政府提出和建议的其他保护主义政策, the effect on the domestic production of pharmaceutical drugs in the US in the long term is projected to be positive.

As American drug producers face accelerated pressure to increase productivity of their domestic manufacturing plants to compete with labour intensive markets, 行业机构预计,自动化和机器人解决方案的需求将会增加. 根据机器人工业协会和ZMR, by 2026, the global pharmaceutical robotic market is expected to reach USD 200 million with an annualised growth rate of almost 13.2%,高于2019年的9300万美元. The International Federation of Robotics (IFR) claims robotic installations in the US pharmaceutical sector increased by 11.2016年至2018年之间的4%, while the trajectory of growth is set to accelerate in line with the growing concern of securing 供应链 with an expected CAGR of 10 percent in the upcoming years. In 2020, life science was the sector showing the highest growth year-to-date in robotic sales order intake in 北美, 根据机器人工业协会的数据,与2019年上半年相比增长了97%.

加强监管需要解决采摘问题 & 包装

在制药制造价值链内, 机器人技术最常用于产品的最后步骤,即提货和包装. 北美, 而美国是主导国家, has the largest market for pharmaceutical packaging globally and forecast figures by Mordor Intelligence suggest sector is expected to grow with a CAGR of 8.到2025年3%. 基于PMMI商业情报进行的调查, 在美国,大约61%的制药企业使用机器人进行包装, and both current and new users are scaling up the implementation of automation in picking and packaging processes. Swedish automation companies offering solutions for flexible configurations with high speed and accuracy could see this area as a particular potential for growth.

There is also a growing need for track and trace solutions as several new regulatory requirements come into force. The Food and Drug Administration (FDA) requires that all produced packages must be labelled with the exact mark approved by the pharmaceutical manufacturer, a process which will benefit from using robotics rather than being controlled by humans - which often is still the case. FDA的目标是到2023年在处方药生产中实现单位级别的可追溯, 通过《cq9传奇电子游戏》实施. Investments in new equipment will help manufacturers adapt to the rules with integrated automation supporting efficiency while maintaining compliance.


For Swedish companies looking to compete with domestic players and grow their footprint in the US pharmaceutical manufacturing sector, a local presence will be critical to meet increased requirements on domestic content while also respond to the mounting pressure to re-shore pharmaceutical manufacturing. 拜登的 购买美国货行为 会加强对美国产品的国内内容和采购流程的规定吗, cq9传奇电子游戏, 供应链, 以及货物的运输. 解决影响药品供应链的关键问题, 操作 and customer landscape is important to create a more resilient and competitive position in the US.

cq9传奇电子游戏的团队 if you want to learn more about opportunities in the US industrial sector and how to navigate the new business landscape.